SBC Medical Group (SBC) Projected to Post Quarterly Earnings on Friday

SBC Medical Group (NASDAQ:SBC) is projected to post its Q4 2025 results before the market opens on Friday, March 27th. Analysts expect SBC Medical Group to post earnings of $0.13 per share and revenue of $45.1890 million for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, March 27, 2026 at 8:30 AM ET.

SBC Medical Group Stock Up 3.7%

NASDAQ:SBC opened at $3.63 on Friday. The firm has a 50-day simple moving average of $4.20 and a two-hundred day simple moving average of $4.06. The firm has a market cap of $372.37 million, a P/E ratio of 8.85 and a beta of 1.19. SBC Medical Group has a fifty-two week low of $2.91 and a fifty-two week high of $5.75. The company has a debt-to-equity ratio of 0.07, a quick ratio of 5.06 and a current ratio of 5.10.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on SBC. BTIG Research assumed coverage on shares of SBC Medical Group in a research report on Friday, March 6th. They set a “buy” rating and a $8.00 price target for the company. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of SBC Medical Group in a research report on Monday, December 29th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $8.50.

Insider Activity at SBC Medical Group

In other news, CEO Yoshiyuki Aikawa sold 4,422,900 shares of the business’s stock in a transaction that occurred on Friday, March 6th. The shares were sold at an average price of $2.12, for a total transaction of $9,376,548.00. Following the completion of the transaction, the chief executive officer directly owned 861,600 shares of the company’s stock, valued at $1,826,592. The trade was a 83.70% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 89.47% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On SBC Medical Group

A number of large investors have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. bought a new position in shares of SBC Medical Group during the 4th quarter valued at $49,000. Russell Investments Group Ltd. grew its holdings in shares of SBC Medical Group by 292.0% in the fourth quarter. Russell Investments Group Ltd. now owns 11,775 shares of the company’s stock worth $51,000 after acquiring an additional 8,771 shares during the period. Nuveen LLC bought a new stake in shares of SBC Medical Group in the fourth quarter worth $53,000. Wells Fargo & Company MN increased its position in SBC Medical Group by 195.1% during the fourth quarter. Wells Fargo & Company MN now owns 12,626 shares of the company’s stock valued at $54,000 after acquiring an additional 8,348 shares during the last quarter. Finally, XTX Topco Ltd purchased a new stake in SBC Medical Group during the second quarter valued at $64,000. Institutional investors own 60.82% of the company’s stock.

About SBC Medical Group

SBC Medical Group, Inc is a publicly traded healthcare management services company listed on the Nasdaq under the ticker SBC. The company specializes in supporting in-office ancillary service providers by offering a suite of administrative and operational solutions designed to streamline practice management and enhance revenue performance. Its core mission is to help physician practices, imaging centers and other ancillary service providers focus on patient care while outsourcing complex back-office functions.

The company’s primary offerings include revenue cycle management, medical billing and coding, compliance oversight and transcription services.